Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EMLA vs ALCAINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
EMLA is a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%. Lidocaine and prilocaine are amide-type local anesthetics that block sodium ion channels in neuronal membranes, inhibiting the initiation and conduction of nerve impulses, thereby producing local analgesia.
Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.
Topical anesthesia of intact skin for superficial procedures,Topical anesthesia of genital mucous membranes for minor superficial procedures,Local analgesia prior to lumbar puncture (off-label),Local analgesia prior to vaccination (off-label)
Ophthalmic anesthesia for procedures such as cataract extraction, tonometry, gonioscopy, and suture removal
Apply a thick layer of cream (approximately 2.5 g per 20 cm²) to intact skin under an occlusive dressing for at least 1 hour for minor procedures; for dermal procedures on larger areas, apply up to 60 minutes before procedure, maximum single application area of 600 cm² in adults.
1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.
After topical application, the terminal elimination half-life of lidocaine is approximately 1.5-2 hours; prilocaine half-life is approximately 1.5 hours. In neonates, half-life may be prolonged due to immature hepatic function. Clinical context: Steady state is achieved within 12-24 hours with repeated application.
Terminal elimination half-life: 0.4–1.2 minutes (rapid enzymatic hydrolysis by plasma esterases); clinical significance: ultra-short duration limits systemic toxicity.
Lidocaine is primarily metabolized by CYP1A2 to monoethylglycinexylidide (MEGX) and further by CYP3A4; prilocaine is metabolized by amidases to o-toluidine metabolites that can oxidize hemoglobin to methemoglobin.
Hydrolyzed by plasma esterases.
Lidocaine and prilocaine are metabolized in the liver; lidocaine metabolites (primarily 4-hydroxyxylidine) and prilocaine metabolites (primarily o-toluidine) are excreted renally. Less than 5% of unchanged lidocaine and prilocaine are excreted unchanged in urine. Fecal excretion is negligible.
Renal excretion of parent drug and metabolites: <5% unchanged.
Lidocaine: 65-70% bound to alpha-1-acid glycoprotein and albumin. Prilocaine: 55% bound to albumin.
Minimal; <5% bound to plasma proteins.
Lidocaine: Vd approximately 1.0-1.5 L/kg; prilocaine: Vd approximately 1.5-2.0 L/kg. Clinical meaning: Large Vd indicates extensive tissue distribution, including into the CNS and adipose tissue.
Not clinically meaningful due to rapid hydrolysis; Vd estimated <0.5 L/kg (low, consistent with high water solubility and rapid clearance).
Topical bioavailability: 20-30% for lidocaine and prilocaine when applied to intact skin under occlusion; higher (up to 80%) on mucous membranes or abraded skin. Systemic absorption is minimal with recommended doses, but can be significant with prolonged application or large surface areas.
Ophthalmic topical: negligible systemic absorption (minimal bioavailability); not applicable systemically.
No dose adjustment required for renal impairment; however, use with caution in patients with severe renal impairment due to potential accumulation of lidocaine and prilocaine metabolites.
No dose adjustment required; negligible systemic absorption.
In Child-Pugh Class B or C, use with caution and consider reduced application area or shorter application time due to reduced metabolism of lidocaine and prilocaine; specific dose modifications not established.
No dose adjustment required; negligible systemic absorption.
Infants and children: Apply 1-2 g per 10 cm², with maximum application area based on weight: 10 cm² for infants 1-3 months, 20 cm² for 3-12 months, 100 cm² for 1-6 years, 200 cm² for 7-12 years; application time 30-60 minutes depending on age and procedure.
1 drop of 0.5% solution topically to the eye, repeated as needed; maximum 1 drop per dose in infants and young children to avoid systemic effects.
No specific dose adjustment; use with caution in elderly due to increased risk of systemic absorption from thinner skin and potential comorbidities; consider smaller application area or shorter duration.
No specific adjustment; use lowest effective dose due to potential increased corneal sensitivity and delayed healing.
EMLA cream can cause methemoglobinemia, especially in children under 12 months, patients with glucose-6-phosphate dehydrogenase deficiency, or those taking oxidizing drugs. Serious and fatal methemoglobinemia has been reported; monitor for signs and symptoms.
Not for injection or prolonged use; corneal toxicity with repeated or prolonged use.
Avoid application to open wounds, mucous membranes (except genital), or areas with altered skin barrier. Use with caution in patients with severely traumatized mucosa or sepsis. Monitor for methemoglobinemia, especially in young children. Do not apply to large areas or for prolonged periods. Consider risk of systemic toxicity if applied to inflamed skin or large areas.
Prolonged use may cause corneal epithelial damage and delay wound healing. Avoid contamination of the dropper tip.
Hypersensitivity to lidocaine, prilocaine, or other amide anesthetics; known history of methemoglobinemia; application to eyes or on tympanic membrane; patients with severe hepatic disease (due to impaired metabolism).
Hypersensitivity to any component of the formulation.
No known food interactions. Avoid alcohol if large amounts of lidocaine/prilocaine are absorbed (rare).
None known.
EMLA (lidocaine 2.5% and prilocaine 2.5%) is FDA Pregnancy Category B. Lidocaine and prilocaine cross the placenta. In first trimester, no increased risk of major malformations in human data. Second and third trimesters: no known fetal harm from topical use. Methemoglobinemia risk in fetus if high doses or prolonged use, especially with prilocaine.
Proparacaine (ALCAINE) is an ophthalmic local anesthetic. Systemic absorption is negligible after topical ocular administration. No adequate well-controlled studies in pregnant women. Animal studies showed no teratogenic effects at doses up to 0.5 mg/kg (SC). Potential fetal risk unlikely to exceed background risk. No known trimester-specific risks.
Lidocaine and prilocaine are excreted into breast milk in low amounts. M/P ratio: lidocaine ~0.4-0.6, prilocaine ~1.0-1.4. Infant dose ~1-2% of maternal weight-adjusted dose. Risk of methemoglobinemia in premature or G6PD-deficient infants. Use with caution.
Proparacaine is excreted into breast milk in unknown amounts, but due to minimal systemic absorption, the expected dose to infant is negligible. Manufacturer advises caution. No M/P ratio available.
No specific dose adjustments required for topical application. Physiologic changes in pregnancy (increased plasma volume, decreased protein binding) do not significantly alter systemic absorption from intact skin. Avoid large areas, prolonged application, or abraded skin to minimize systemic load.
No dosing adjustment required for topical ophthalmic use due to negligible systemic absorption and lack of pharmacokinetic alterations in pregnancy.
EMLA (eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) requires at least 60 minutes of occlusive application for dermal analgesia. Apply to intact skin only; avoid mucous membranes due to rapid absorption. Do not use in infants <37 weeks postconceptual age due to methemoglobinemia risk. Maximum application area: 10% body surface in infants. Onset is slower on thicker skin (e.g., back vs. antecubital). Remove cream after 4 hours to prevent systemic toxicity.
ALCAINE (proparacaine) is a topical ophthalmic anesthetic. Onset within 20 seconds, duration ~15 minutes. Do not dispense for home use due to risk of corneal toxicity with prolonged use. Use a sterile, single-dose vial to prevent contamination. Monitor for stinging or burning on instillation. Avoid in patients with sulfite allergy (contains sodium bisulfite).
Apply a thick layer (1-2 mm) to intact skin and cover with occlusive dressing for at least 60 minutes before procedure.,Do not use on broken skin, eyes, or near mucous membranes.,Wash hands after application and avoid touching eyes.,Remove cream and dressing just before procedure; do not leave on longer than 4 hours.,Possible mild skin reactions: blanching, redness, swelling. Serious allergic reactions are rare but seek medical help if difficulty breathing or hives occur.,Inform your doctor if you have liver disease, G6PD deficiency, or are taking other numbing medicines.
Temporary stinging or burning may occur upon application.,Do not touch the dropper tip to any surface to avoid contamination.,Do not use for more than instructed; prolonged use can damage the cornea.,Remove contact lenses before use and wait at least 15 minutes before reinserting.,Notify your doctor if you have a sulfite allergy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EMLA vs ALCAINE, answered by our medical review team.
EMLA is a Local Anesthetic that works by EMLA is a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%. Lidocaine and prilocaine are amide-type local anesthetics that block sodium ion channels in neuronal membranes, inhibiting the initiation and conduction of nerve impulses, thereby producing local analgesia.. ALCAINE is a Local Anesthetic that works by Local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion influx, thereby blocking nerve impulse transmission.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EMLA and ALCAINE depend on the specific clinical indication. These are both Local Anesthetic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EMLA is: Apply a thick layer of cream (approximately 2.5 g per 20 cm²) to intact skin under an occlusive dressing for at least 1 hour for minor procedures; for dermal procedures on larger areas, apply up to 60 minutes before procedure, maximum single application area of 600 cm² in adults.. The standard adult dose of ALCAINE is: 1 to 2 drops of 0.5% solution topically to the eye, repeated as needed for anesthesia.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EMLA and ALCAINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EMLA is classified as Category C. EMLA (lidocaine 2.5% and prilocaine 2.5%) is FDA Pregnancy Category B. Lidocaine and prilocaine cross the placenta. In first trimester, no increased risk of major malformations in . ALCAINE is classified as Category C. Proparacaine (ALCAINE) is an ophthalmic local anesthetic. Systemic absorption is negligible after topical ocular administration. No adequate well-controlled studies in pregnant wom. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.